Hormone therapy for relieving postmenopausal vasomotor symptoms: A systematic review

Archives of Iranian Medicine

Volumn 19, Issue 2, 2016, Pages 141-146

  Abdi, Fatemeh ^a   Mobedi, Hamid ^b   Mosaffa, Nariman ^a   Dolatian, Mahrokh ^a   Tehrani, Fahimeh Ramezani ^c  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRAN POLYMER AND PETROCHEMICAL INSTITUTE   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hormone therapy; Menopause; Vasomotor symptoms

Indexed keywords

ESTROGEN; GESTAGEN;

CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; HORMONAL THERAPY; HUMAN; LOW DRUG DOSE; MENOPAUSAL SYNDROME; META ANALYSIS (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; VASOMOTOR DISORDER; ADRENERGIC SYSTEM; ESTROGEN THERAPY; FEMALE; HOT FLASHES; POSTMENOPAUSE; RISK FACTOR; SWEATING;

ESTROGEN REPLACEMENT THERAPY; FEMALE; HOT FLASHES; HUMANS; POSTMENOPAUSE; RISK FACTORS; SWEATING; VASOMOTOR SYSTEM;

EID: 84957542046     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Farahmand M, Tehrani FR, Pourrajabi L, Najafi M, Azizi F. Factors associated with menopausal age in Iranian women: Tehran Lipid and Glucose Study. J Obstet Gynaecol Res. 2013; 39(4): 836-841.
2. Nosek M KH, Gudmundsdottir M. Distress during the menopause transition a rich contextual analysis of midlife women's narratives. Sage Open. 2012; 2(3). Available from: URL: http://sgo.sagepub.com/con-tent/2/3/2158244012455178.
3. Harris MT. Menopause: the need for a paradigm shift from disease to women's health: Southern Cross University, Lismore, NSW.; 2013.
4. Rees M, Moghimi SM. Nanotechnology: from fundamental concepts to clinical applications for healthy aging. Nanomedicine. 2012; 8(Suppl 1): S1-S4.
5. Rubinstein H. The meanings of menopause: identifying the bio-psycho-social predictors of the propensity for treatment at menopause. University of Cambridge; 2013. Available from: URL: https://www.repository.cam.ac.uk/handle/1810/245082
6. Rajaeefard A Mohamadbeigi A, Mohammadsalehi N. The estimated mean age at menopause in Iranian women: a study Mtanalyz. Komesh. 2011; 1(41): 1-7.
7. Heydari LSZ, Sayehmiri F, Sayehmir K. Effect of herbaceous medicines effective in hot flashes of menopause women: a systematic review and meta-analysis in Iran. Iran J Obstet Gynecol Infertil. 2014; 17(109): 16-25.
8. Rotem M, Kushnir T, Levine R, Ehrenfeld M. A Psycho-educational program for improving women's attitudes and coping with menopause symptoms. J Obstet Gynecol Neonatal Nurs. 2005; 34(2): 233-240.
9. Reid R, Blake J, Abramson B, Khan A, Senikas V, Fortier M. Menopause and osteoporosis update 2009. J Obstet Gynaecol Can. 2009; 31(1Suppl 1): S27-S30.
10. Simon JA, Group ES. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms. Menopause. 2006; 13(2): 222-231.
11. Perrone AM, Pozzati F, Santini D, Rossi M, Procaccini M, Casalini L, et al. Gynecological malignancies and hormonal therapies: Clinical management and recommendations. World J Obstet Gynecol. 2014; 3(4): 162-170.
12. Ramezani Tehrani F, Behboudi-Gandevani S, Ghanbarian A, Azizi F. Effect of menopause on cardiovascular disease and its risk factors: a 9-year follow-up study. Climacteric. 2014; 17(2): 164-172.
13. Gurney EP, Nachtigall MJ, Nachtigall LE, Naftolin F. The women's health initiative trial and related studies: 10 years later: a clinician's view. J Steroid Biochem Mol Biol. 2014; 142: 4-11.
14. Whelan AM, Jurgens TM, Trinacty M. Bioidentical progesterone cream for menopause-related vasomotor symptoms: is it effective? Ann Phar-macother. 2013; 47(1): 112-116.
15. de Villiers TJ, Pines A, Panay N, Gambacciani M, Archer DF, Baber RJ, et al. Updated 2013 international menopause society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2013; 16(3): 316-337.
16. Bair YA, Gold EB, Zhang G, Rasor N, Utts J, Upchurch DM, et al. Use of complementary and alternative medicine during the menopause transition: longitudinal results from the Study of Women's Health Across the Nation. Menopause. 2008; 15(1): 32-43.
17. Ramezani Tehrani F, Bahri M, Gholami R, Hashemi S, Nakhoda K, Azizi F. Secular trend of menopausal age and related factors among Tehrani women born from 1930 to 1960; Tehran Lipid and Glucose Study. Arch Iran Med. 2014; 17(6): 406-410.
18. NAMS. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause. 2004; 11(1): 11-33.
19. Hakimi S, Simbar M, Ramezani Tehrani F. Perceived concerns of Az-eri menopausal women in Iran. Iran Red Crescent Med J. 2014; 16(5): e11771.
20. Newton KM, Carpenter JS, Guthrie KA, Anderson GL, Caan B, Cohen LS, et al. Methods for the design of vasomotor symptom trials: the menopausal strategies: finding lasting answers to symptoms and health network. Menopause. 2014; 21(1): 45-58.
21. Blumel JE, Chedraui P, Baron G, Belzares E, Bencosme A, Calle A, et al. A large multinational study of vasomotor symptom prevalence, duration, and impact on quality of life in middle-aged women. Menopause. 2011; 18(7): 778-785.
22. Politi MC, Schleinitz MD, Col NF. Revisiting the duration of vasomo-tor symptoms of menopause: a meta-analysis. J Gen Intern Med. 2008; 23(9): 1507-1513.
23. Thurston RC, Joffe H. Vasomotor symptoms and menopause: findings from the Study of Women's Health across the Nation. Obstet Gynecol Clin North Am. 2011; 38(3): 489-501.
24. Crandall CJ, Crawford SL, Gold EB. Vasomotor symptom prevalence is associated with polymorphisms in sex steroid-metabolizing enzymes and receptors. Am J Med. 2006; 119(9 Suppl 1): S52-S60.
25. Smith AL, Wein AJ. Estrogen replacement therapy for the treatment of postmenopausal genitourinary tract dysfunction. Discov Med. 2010; 10(55): 500-510.
26. Gold EB, Colvin A, Avis N, Bromberger J, Greendale GA, Powell L, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation. Am J Public Health. 2006; 96(7): 1226-1235.
27. Ford K, Sowers M, Crutchfield M, Wilson A, Jannausch M. A longitudinal study of the predictors of prevalence and severity of symptoms commonly associated with menopause. Menopause. 2005; 12(3): 308-317.
28. Melby MK, Anderson D, Sievert LL, Obermeyer CM. Methods used in cross-cultural comparisons of vasomotor symptoms and their determinants. Maturitas. 2011; 70(2): 110-119.
29. Aidelsburger P, Schauer S, Grabein K, Wasem J. Alternative methods for the treatment of post-menopausal troubles. GMSHealth TechnolAssess. 2012; 8: Doc03.
30. Umland EM, Falconieri L. Treatment options for vasomotor symptoms in menopause: focus on desvenlafaxine. Int J Womens Health. 2012; 4: 305-319.
31. Keenan NL, Mark S, Fugh-Berman A, Browne D, Kaczmarczyk J, Hunter C. Severity of menopausal symptoms and use of both conventional and complementary/alternative therapies. Menopause. 2003; 10(6): 507-515.
32. Depypere HT, Comhaire FH. Herbal preparations for the menopause: beyond isoflavones and black cohosh. Maturitas. 2014; 77(2): 191-194.
33. Hickey M, Saunders C, Partridge A, Santoro N, Joffe H, Stearns V. Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. Ann Oncol. 2008; 19(10): 1669-1680.
34. Kam IW, Dennehy CE, Tsourounis C. Dietary supplement use among menopausal women attending a San Francisco health conference. Menopause. 2002; 9(1): 72-78.
35. Al-Safi ZA, Santoro N. Menopausal hormone therapy and menopausal symptoms. Fertil Steril. 2014; 101(4): 905-915.
36. Carris N, Kutner S, Reilly-Rogers S. New pharmacological therapies for vasomotor symptom management: focus on bazedoxifene/conju-gated estrogens and paroxetine mesylate. Ann Pharmacother. 2014; 48(10): 1343-1349.
37. Theroux R. Women's decision making during the menopausal transition. J Am Acad Nurse Pract. 2010; 22(11): 612-621.
38. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013; 310(13): 1353-1368.
39. Stephenson K, Neuenschwander PF, Kurdowska AK. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmeno-pausal women. Int J Pharm Compd. 2013; 17(1): 74-85.
40. Bertelli G, Venturini M, Del Mastro L, Bergaglio M, Sismondi P, Biglia N, et al. Intramuscular depot medroxyprogesterone versus oral meges-trol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study. Ann Oncol. 2002; 13(6): 883-888.
41. Cravioto MD, Durand-Carbajal M, Jimenez-Santana L, Lara-Reyes P, Seuc AH, Sanchez-Guerrero J. Efficacy of estrogen plus progestin on menopausal symptoms in women with systemic lupus erythematosus: a randomized, double-blind, controlled trial. Arthritis Care Res. 2011; 63(12): 1654-1663.
42. Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004; (4): CD002978.
43. Egras AM, Umland EM. The role of transdermal estrogen sprays and estradiol topical emulsion in the management of menopause-associated vasomotor symptoms. Int J Gen Med. 2010; 3: 147-151.
44. Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. 2005; 8 (Suppl 1): 3-63.
45. Minkin MJ. Considerations in the choice of oral vs. transdermal hormone therapy: a review. JReprodMed. 2004; 49(4): 311-320.
46. Archer DF. Tissue-selective estrogen complexes: a promising option for the comprehensive management of menopausal symptoms. Drugs Aging. 2010; 27(7): 533-544.
47. Botelho MA, Queiroz DB, Barros G, Guerreiro S, Fechine P, Umbelino S, et al. Nanostructured transdermal hormone replacement therapy for relieving menopausal symptoms: a confocal Raman spectroscopy study. Clinics. 2014; 69(2): 75-82.
48. Buster JE, Koltun WD, Pascual ML, Day WW, Peterson C. Low-dose estradiol spray to treat vasomotor symptoms: a randomized controlled trial. Obstet Gynecol. 2008; 111(6): 1343-1351.
49. Simon JA. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms. Menopause. 2006; 13(2): 222-231.
50. Ruiz AD, Daniels KR. The effectiveness of sublingual and topical compounded bioidentical hormone replacement therapy in postmenopausal women: an observational cohort study. Int JpharmCompd. 2014; 18(1): 70-77.
51. Bachmann GA, Schaefers M, Uddin A, Utian WH. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmeno-pausal women: a randomized controlled trial. Obstet Gynecol. 2007; 110(4): 771-779.
52. Joffe H, Guthrie KA, LaCroix AZ, Reed SD, Ensrud KE, Manson JE. Randomized controlled trial of low-dose estradiol and the SNRI venla-faxine for vasomotor symptoms. JAMA Intern Med. 2014; 174(7): 1058-1066.
53. Shulman LP, Yankov V, Uhl K. Safety and efficacy of a continuous once-a-week 17beta-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmeno-pausal women: the results of two multicenter, double-blind, randomized, controlled trials. Menopause. 2002; 9(3): 195-207.
54. Hedrick RE, Ackerman RT, Koltun WD, Halvorsen MB, Lambrecht LJ. Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women. Menopause. 2009; 16(1): 132-140.
55. Struzzo P, Fumato R, Tillati S, Cacitti A, Gangi F, Stefani A, et al. Individual empowerment in overweight and obese patients: a study protocol. BMJ. 2013; 3(5). pii: e002669.
56. Ratka A, Miller V, Brown K, Jenschke M, Simpkins J. Association of various dimensions of hot flashes with systemic levels of gonadal steroids. Exp Biol Med (Maywood). 2009; 234(4): 395-402.
57. Nachtigall LE, Baber RJ, Barentsen R, Durand N, Panay N, Pitkin J, et al. Complementary and hormonal therapy for vasomotor symptom relief: a conservative clinical approach. J Obstetrics Gynaecol Can. 2006; 28(4): 279-289.
58. Utian WH, Archer DF, Bachmann GA, Gallagher C, Grodstein F, Heiman JR, et al. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause. 2008; 15(4 Pt 1): 584-602.
59. Cobin RH, Futterweit W, Ginzburg SB, Goodman NF, Kleerekoper M, Licata AA, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause. EndocrPract. 2006; 12(3): 315-337.